severe asthma therapies
Sep 12, 2022
How Emerging Pipeline Therapies Will Unfold the Severe Asthma Treatment Market Dynamics?
Key Highlights Tezspire (tezepelumab) with no phenotypic (eosinophilic or allergic) or biomarker restriction will be the new game-changer in the severe asthma marketDepemokimab is an excellent market replacement for GSKs’ Nucala as of its improved binding affinity and longer duration of action as a single doseNo...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
